[Translation] A multicenter, open-label phase I clinical study evaluating the safety, tolerability, and preliminary efficacy of HD004 cell intraperitoneal infusion therapy in patients with advanced solid tumors expressing CLDN18.2 and malignant ascites.
主要研究目的:评估HD004细胞腹腔灌注治疗CLDN18.2表达阳性的晚期实体肿瘤伴恶性腹腔积液患者的安全性和耐受性,并确定MTD或RP2D。
次要研究目的:(1)评估HD004细胞在研究参与者体内的药代动力学(PK)特征。(2)评估HD004细胞的免疫原性。(3)评估HD004细胞腹腔灌注后研究参与者体内复制性慢病毒(RCL)情况。(4)评估HD004细胞腹腔灌注治疗CLDN18.2表达阳性的晚期实体肿瘤伴恶性腹腔积液患者的有效性。
探索性研究目的:(1)探索CLDN18.2的表达水平与疗效的相关性。(2)探索腹腔积液及血液中药代动力学(PK)、药效动力学(PD)指标与疗效和安全性的关系。(3)评估HD004细胞腹腔灌注治疗CLDN18.2表达阳性的晚期实体肿瘤的初步有效性。
[Translation] Primary Objective: To evaluate the safety and tolerability of intraperitoneal perfusion of HD004 cells in patients with CLDN18.2-positive advanced solid tumors and malignant ascites, and to determine the mean time to death (MTD) or recurrent pulmonary edema (RP2D).
Secondary Objectives: (1) To evaluate the pharmacokinetic (PK) characteristics of HD004 cells in study participants. (2) To evaluate the immunogenicity of HD004 cells. (3) To evaluate the status of replicating lentiviruses (RCLs) in study participants after intraperitoneal perfusion of HD004 cells. (4) To evaluate the efficacy of intraperitoneal perfusion of HD004 cells in patients with CLDN18.2-positive advanced solid tumors and malignant ascites.
Exploratory Objectives: (1) To explore the correlation between CLDN18.2 expression levels and efficacy. (2) To explore the relationship between pharmacokinetic (PK) and pharmacodynamic (PD) indicators in ascites and blood and efficacy and safety. (3) To evaluate the preliminary efficacy of intraperitoneal perfusion of HD004 cells in patients with CLDN18.2-positive advanced solid tumors.